Table 3. Self-Reported Outcomes at 16-Week Follow-Up.
| Outcome | Participants, No. (%) | Propensity score, AOR (95% CI)a | ||
|---|---|---|---|---|
| Total (N = 335) | Bridge clinic (n = 167) | Usual care (n = 168) | ||
| Opioid use within past 30 d | NA | NA | NA | 46.94 (9.28-237.35) |
| No use | 4 (1.2) | 2 (1.2) | 2 (1.2) | NA |
| Single use | 4 (1.2) | 0 | 4 (2.4) | NA |
| Multiple use | 24 (7.2) | 17 (10.2) | 7 (4.2) | NA |
| Unable to recontact at 16 wk | 303 (90.4) | 148 (88.6) | 155 (92.3) | NA |
| Recurrent opioid use | NA | NA | NA | 0.70 (0.42-1.18) |
| Yes | 38 (11.3) | 23 (13.8) | 15 (8.9) | NA |
| No | 50 (14.9) | 33 (19.8) | 17 (10.1) | NA |
| Unable to recontact at 16 wk | 247 (73.7) | 111 (66.5) | 136 (81.0) | NA |
| Overdose | NA | NA | NA | 0.11 (0.03-0.41) |
| Yes | 5 (1.5) | 1 (0.6) | 4 (2.4) | NA |
| No | 81 (24.2) | 53 (31.7) | 28 (16.7) | NA |
| Unable to recontact at 16 wk | 249 (74.3) | 113 (67.7) | 136 (81.0) | NA |
| Linkage to health care professional who provided MOUD | NA | NA | NA | 2.37 (1.32-4.26) |
| Yes | 64 (19.1) | 45 (26.9) | 19 (11.3) | NA |
| No | 24 (7.2) | 11 (6.6) | 13 (7.7) | NA |
| Unable to recontact at 16 wk | 247 (73.7) | 111 (66.5) | 136 (81.0) | NA |
| No. of buprenorphine fills, median (IQR) | 6.0 (0.0-15.0) | 10.0 (4.0-16.0) | 1.0 (0.0-6.0) | 6.17 (3.69-10.30) |
| Missing | 258 (77.0) | 121 (72.5) | 137 (81.5) | NA |
| Quality of Life SOS10 score, median (IQR) | 44.0 (29.5-54.0) | 47.0 (26.0-53.8) | 41.5 (32.5-54.3) | 0.90 (0.58-1.38) |
| Missing | 249 (74.3) | 113 (67.7) | 136 (81.0) | NA |
Abbreviations: AOR, adjusted odds ratio; MOUD, medication for opioid use disorder; NA, not applicable; SOS10, Schwartz Outcome Scale–10.
a
Calculated for 16-week self-reported outcomes.